Core Viewpoint - A class action lawsuit has been filed against Baxter International Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of Illinois, captioned Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International Inc., et al., No. 1:25-cv-12672 [3]. - Investors have until December 15, 2025, to request to be appointed to lead the case [3]. Group 2: Product Issues - Baxter's Novum IQ Large Volume pump, a key growth driver, has faced serious malfunctions, including under- and over-medication of patients, since its launch in Canada in 2020 [4][5]. - The company previously claimed that the Novum LVP had "the most advanced safety features" and would provide "a safer delivery of medication," which is now alleged to be misleading [5]. Group 3: Stock Impact - Following the announcement on July 31, 2025, that Baxter would "voluntarily and temporarily pause shipments and planned installations" of the Novum LVP, the stock price fell by $6.29, or over 22%, from $28.05 to $21.76 per share [6].

Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. due to alleged securities fraud affecting investors between February 23, 2022, and July 30, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Baxter's Novum LVP product had systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [2]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths related to these defects [2]. - The company's attempts to address these issues through customer alerts were deemed inadequate, as design flaws persisted and continued to harm patients [2]. - There was an increased risk that customers would be instructed to take existing Novum LVPs out of service, and Baxter might halt all new sales of these pumps [2]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were alleged to be materially false and misleading [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request appointment as lead plaintiff, although participation does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Baxter International, Inc. ("Baxter†or the "Company†) (NYSE: BAX) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON BAXTER INTERNATIONAL, INC. (BAX), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened. ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Baxter International Inc. due to allegations of false and misleading statements regarding the Novum LVP medical device, which has been linked to serious malfunctions and patient risks [3][4]. Group 1: Allegations Against Baxter - The complaint alleges that Baxter and its executives violated federal securities laws by failing to disclose systemic defects in the Novum LVP, which caused malfunctions such as underinfusion and overinfusion, exposing patients to serious injury or death [3]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths related to these defects but did not take adequate remedial measures [3]. - The company's statements regarding the safety, efficacy, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [3]. Group 2: Impact on Stock and Legal Proceedings - On July 31, 2025, Baxter announced a voluntary and temporary pause in shipments and installations of the Novum LVP, leading to a 22.4% drop in stock price, closing at $21.76 [4]. - Investors who purchased Baxter securities between February 23, 2022, and July 30, 2025, are encouraged to discuss their legal rights and options with Faruqi & Faruqi, with a deadline of December 15, 2025, to seek the role of lead plaintiff in the class action [1][5].

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Baxter International, Inc. ("Baxter†or the "Company†) (NYSE: BAX) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN BAXTER INTERNATIONAL, INC. (BAX), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal ri. ...

Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to allegations of misleading statements and undisclosed systemic defects in its Novum IQ Large Volume Pump, which have resulted in serious risks to patients and significant stock price decline [3][4]. Group 1: Class Action Details - The class action is on behalf of investors who purchased Baxter securities between February 23, 2022, and July 30, 2025, with a deadline of December 15, 2025, for filing a lead plaintiff motion [1]. - The lawsuit claims that Baxter's Novum IQ LVP suffered from systemic defects leading to malfunctions such as underinfusion and overinfusion, posing risks of serious injury or death to patients [3]. - Baxter was allegedly aware of multiple device malfunctions and injuries but failed to take adequate remedial measures, which continued to expose patients to harm [3]. Group 2: Impact on Company Operations - On July 31, 2025, Baxter announced a voluntary and temporary pause in shipments and installations of the Novum LVP, unable to provide a timeline for resuming operations [4]. - The company suggested an alternative product, the Spectrum infusion pump, to customers while indicating that its low-end guidance assumes no resumption of Novum LVP shipments before year-end [4]. - Following the announcement, Baxter's stock price dropped by more than 22%, reflecting investor concerns over the ongoing issues with the Novum LVP [4].

Group 1 - Baxter International, Inc. is facing a securities fraud class action lawsuit due to reported losses suffered by investors [1] - Investors have until December 15, 2025, to request the Court to appoint them as lead plaintiff in the lawsuit [1]

Core Viewpoint - Baxter International, Inc. is under investigation for potential violations of federal securities laws, which may impact investors who have incurred losses [1] Investigation Details - The investigation is initiated by the Law Offices of Frank R. Cruz on behalf of investors [1] - A report from a Missouri news outlet on April 7, 2025, highlighted serious concerns regarding the company's practices [1]

Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to allegations of issuing false and misleading statements regarding the safety and efficacy of its Novum LVP product, which reportedly has systemic defects leading to serious patient risks [3][4]. Summary by Relevant Sections Allegations - The lawsuit claims that Baxter's Novum LVP product suffered from systemic defects causing malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing risks of serious injury or death to patients [3]. - Baxter was allegedly aware of multiple device malfunctions, injuries, and deaths related to these defects but failed to adequately address them [3]. - The company's attempts to mitigate these issues through customer alerts were deemed insufficient, as design flaws persisted [3]. - There was an increased risk that customers would be advised to take existing Novum LVPs out of service, and Baxter might halt all new sales of these pumps [3]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [3]. Class Action Details - The class period for the lawsuit is from February 23, 2022, to July 30, 2025 [3]. - Shareholders are encouraged to register for the class action by December 15, 2025, to potentially become lead plaintiffs [4]. - Participation in the case does not require appointment as lead plaintiff, and there is no cost or obligation for shareholders to register [4]. Law Firm Information - The Gross Law Firm is representing the shareholders and is recognized for its commitment to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Baxter International Inc. (NYSE: BAX) and certain of the Company’s senior executives for securities fraud after significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Baxter, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/baxter-international-inc ...